RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease
Kilian M. Gust, Matthias D. Hofer, Sven R. Perner, Robert Kim, Arul M. Chinnaiyan, Sooryanarayana Varambally, Peter Moller, Ludwig Rinnab, Mark A. Rubin, Jochen Greiner, Michael Schmitt, Rainer Kuefer*, Mark Ringhoffer
Untersuchen Sie die Forschungsthemen von „RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease“. Zusammen bilden sie einen einzigartigen Fingerprint.